Financial Contrast: Taysha Gene Therapies (NASDAQ:TSHA) versus AIM ImmunoTech (NYSE:AIM)

Taysha Gene Therapies (NASDAQ:TSHA) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, analyst recommendations, profitability, institutional ownership and valuation.

Valuation and Earnings

This table compares Taysha Gene Therapies and AIM ImmunoTech”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.92 million	36.38	-$111.57 million	$0.63	2.79
AIM ImmunoTech	$190,000.00	72.17	-$28.96 million	($0.47)	-0.46

AIM ImmunoTech has lower revenue, but higher earnings than Taysha Gene Therapies. AIM ImmunoTech is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Taysha Gene Therapies has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.36, meaning that its share price is 136% less volatile than the S&P 500.

Profitability

This table compares Taysha Gene Therapies and AIM ImmunoTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	-229.67%	-106.36%	-49.16%
AIM ImmunoTech	-12,594.21%	-421.73%	-147.54%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Taysha Gene Therapies and AIM ImmunoTech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	0	0	8	0	3.00
AIM ImmunoTech	0	0	2	0	3.00

Taysha Gene Therapies presently has a consensus target price of $6.63, indicating a potential upside of 276.42%. AIM ImmunoTech has a consensus target price of $2.75, indicating a potential upside of 1,179.07%. Given AIM ImmunoTech’s higher possible upside, analysts clearly believe AIM ImmunoTech is more favorable than Taysha Gene Therapies.

Institutional and Insider Ownership

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 2.7% of Taysha Gene Therapies shares are held by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Taysha Gene Therapies beats AIM ImmunoTech on 10 of the 13 factors compared between the two stocks.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.